Lupin is currently trading at Rs. 1469.00, up by 8.00 points or 0.55% from its previous closing of Rs. 1461.00 on the BSE.
The scrip opened at Rs. 1460.00 and has touched a high and low of Rs. 1472.00 and Rs. 1456.15 respectively. So far 9091 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1874.30 on 14-Mar-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1482.40 and Rs. 1450.00 respectively. The current market cap of the company is Rs. 66302.66 crore.
The promoters holding in the company stood at 46.71%, while Institutions and Non-Institutions held 41.46% and 11.83% respectively.
Lupin has launched generic Pristiq (Desvenlafaxine Succinate) Extended-Release Tablets, 50 mg and 100 mg having received an approval from the United States Food and Drug Administration (USFDA) earlier. Lupin’s Desvenlafaxine Succinate Extended-Release Tablets, 50 mg and 100 mg, is the AB rated generic equivalent of Wyeth Pharmaceuticals’ Pristiq Tablets. It is indicated for the treatment of major depressive disorder (MDD). Pristiq tablets had annual US sales of around $859.9 million as per IMS MAT December 2016.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.